JP2020512368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512368A5 JP2020512368A5 JP2019553442A JP2019553442A JP2020512368A5 JP 2020512368 A5 JP2020512368 A5 JP 2020512368A5 JP 2019553442 A JP2019553442 A JP 2019553442A JP 2019553442 A JP2019553442 A JP 2019553442A JP 2020512368 A5 JP2020512368 A5 JP 2020512368A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- composition according
- synuclein
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479818P | 2017-03-31 | 2017-03-31 | |
| US62/479,818 | 2017-03-31 | ||
| US201762528790P | 2017-07-05 | 2017-07-05 | |
| US62/528,790 | 2017-07-05 | ||
| PCT/IB2018/052236 WO2018178950A1 (en) | 2017-03-31 | 2018-03-30 | Compositions and methods for treating synucleinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512368A JP2020512368A (ja) | 2020-04-23 |
| JP2020512368A5 true JP2020512368A5 (https=) | 2021-05-06 |
Family
ID=62092178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553442A Withdrawn JP2020512368A (ja) | 2017-03-31 | 2018-03-30 | シヌクレイノパチーを治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200377579A1 (https=) |
| EP (1) | EP3630815A1 (https=) |
| JP (1) | JP2020512368A (https=) |
| KR (1) | KR20200026789A (https=) |
| CN (1) | CN110997715A (https=) |
| AU (1) | AU2018242626A1 (https=) |
| BR (1) | BR112019020335A2 (https=) |
| CA (1) | CA3058304A1 (https=) |
| IL (1) | IL269637A (https=) |
| JO (1) | JOP20190227A1 (https=) |
| MA (1) | MA48730A (https=) |
| SG (1) | SG11201908672WA (https=) |
| WO (1) | WO2018178950A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009328505B2 (en) | 2008-12-19 | 2014-11-27 | Panima Pharmaceuticals Ag | Human anti-alpha-synuclein autoantibodies |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| JP2021502955A (ja) * | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | シヌクレイン病の治療のための投与レジメン |
| US20190153102A1 (en) | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| WO2020079113A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| CA3159964A1 (en) * | 2019-12-04 | 2021-06-10 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| IL301039A (en) | 2020-09-10 | 2023-05-01 | Prothena Biosciences Ltd | Treatment of parkinson's disease |
| KR20240055758A (ko) | 2021-09-16 | 2024-04-29 | 하. 룬드벡 아크티에셀스카브 | 시누클레인병증을 치료하기 위한 조성물 및 방법 |
| WO2024167821A2 (en) * | 2023-02-06 | 2024-08-15 | Creative Bio-Peptides, Inc. | Peptides for treating neurological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| AU2009328505B2 (en) * | 2008-12-19 | 2014-11-27 | Panima Pharmaceuticals Ag | Human anti-alpha-synuclein autoantibodies |
| HUE041391T2 (hu) * | 2011-06-23 | 2019-05-28 | Biogen Int Neuroscience Gmbh | Anti-alfa-szinukleinkötõ molekulák |
| UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
-
2017
- 2017-06-16 JO JOP/2019/0227A patent/JOP20190227A1/ar unknown
-
2018
- 2018-03-30 CN CN201880026858.1A patent/CN110997715A/zh active Pending
- 2018-03-30 MA MA048730A patent/MA48730A/fr unknown
- 2018-03-30 JP JP2019553442A patent/JP2020512368A/ja not_active Withdrawn
- 2018-03-30 WO PCT/IB2018/052236 patent/WO2018178950A1/en not_active Ceased
- 2018-03-30 CA CA3058304A patent/CA3058304A1/en active Pending
- 2018-03-30 US US16/497,055 patent/US20200377579A1/en not_active Abandoned
- 2018-03-30 KR KR1020197030675A patent/KR20200026789A/ko not_active Abandoned
- 2018-03-30 BR BR112019020335A patent/BR112019020335A2/pt not_active IP Right Cessation
- 2018-03-30 SG SG11201908672W patent/SG11201908672WA/en unknown
- 2018-03-30 EP EP18721459.8A patent/EP3630815A1/en not_active Withdrawn
- 2018-03-30 AU AU2018242626A patent/AU2018242626A1/en not_active Abandoned
-
2019
- 2019-09-25 IL IL26963719A patent/IL269637A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512368A5 (https=) | ||
| JP7725185B2 (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| JP2023029882A (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| JP2020141669A5 (https=) | ||
| JP2020503260A5 (https=) | ||
| JP2019517540A5 (https=) | ||
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2022093640A (ja) | 抗ｉｌ－１治療に関する新しい適応症 | |
| JP2019527194A5 (https=) | ||
| CN114173816A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| CN114558129A (zh) | 用于降低心血管风险的方法 | |
| HK1244229A1 (zh) | 治疗CROHN病的整联蛋白β7拮抗剂和方法 | |
| Faissner et al. | Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments | |
| JP2013538796A5 (https=) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| US12116407B2 (en) | Methods of treating neurodegenerative diseases | |
| JP2019503706A5 (https=) | ||
| JP2018526330A5 (https=) | ||
| JP2018516933A (ja) | 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法 | |
| JP2020527152A5 (https=) | ||
| JP2019532970A5 (https=) | ||
| Kleinschnitz et al. | Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006 | |
| JP2020505350A5 (https=) | ||
| US20230287133A1 (en) | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab | |
| CA3199806A1 (en) | Methods of reducing tau in human subjects |